# Aspen Neuroscience

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/aspen-neuroscience

- Industry: Biotechnology
- Headquarters: San Diego, US
- Website: www.aspenneuroscience.com
- Total disclosed funding: $339M
- Latest round: Series C (Nov 20, 2025)
- Investors on record: 21

## About

Aspen Neuroscience, Inc., based in the US, specializes in innovative cell therapy solutions aimed at treating neurological conditions, particularly Parkinson's disease. Founded in 2018 and headquartered in San Diego, California, Aspen Neuroscience develops advanced therapies utilizing autologous induced pluripotent stem cells (iPSCs). The firm has attracted attention for its product ANPD001, targeting the restoration of dopamine neurons in Parkinson’s patients. In November 2025, Aspen Neuroscience, Inc. raised USD 115 million in series C funding from OrbiMed, Frazier Life Sciences, ARCH Venture Partners, Revelation Capital Management, Medical Excellence Capital, Axon Ventures, Section 32, LifeForce Capital, LYFE Capital, Kite Pharma, Inc., Prebys Foundation, Cormorant Asset Management and BAM Elevate. Aspen Neuroscience specializes in personalized cell therapy, offering the world's first autologous iPSC-derived neuron replacement therapy designed for Parkinson's disease. The therapy, ANPD001, addresses the severe loss of dopamine neurons in affected patients, which can exceed 50% before diagnosis. It involves reprogramming a small sample of the patient's skin cells into unique iPSCs, with the aim of restoring neuronal function and enhancing patient quality of life. Currently, ANPD001 is undergoing the Phase 1/2a ASPIRO clinical trial to assess its effectiveness within the U.S. market, targeting individuals with Parkinson's and collaborating healthcare institutions. Aspen Neuroscience is in the investigational stage with ANPD001, which is not yet approved for commercial sale. Therefore, the company does not generate revenue from direct sales. Its business model relies on investments and partnerships within clinical trials, focusing on research and development costs. Future revenue will depend on the successful commercialization of ANPD001 following FDA approval, at which point the company will establish pricing strategies for healthcare facilities and potential pharmaceutical distributors. In November 2025, Aspen Neuroscience, Inc. raised USD 115 million in series C funding from OrbiMed, Frazier Life Sciences, ARCH Venture Partners, Revelation Capital Management, Medical Excellence Capital, Axon Ventures, Section 32, LifeForce Capital, LYFE Capital, Kite Pharma, Inc., Prebys Foundation, Cormorant Asset Management and BAM Elevate. The company will use the funding to advance clinical development of ANPD001 for Parkinson’s disease, expand manufacturing capabilities, and support additional pipeline therapies.

## Funding rounds

- Series C, Nov 20, 2025, $115M — ARCH Venture Partners, Frazier Healthcare Partners, OrbiMed Advisors, Kite Pharma, Inc., Cormorant Asset Management, Revelation Partners, LYFE Capital, Section 32, LifeForce Capital, BAM Elevate, Medical Excellence Capital, Prebys Foundation, Axon Ventures
- Series B, May 9, 2022, $148M — ARCH Venture Partners, Frazier Healthcare Partners, OrbiMed Advisors, Alexandria Venture Investments, SG Growth Capital, GV, Mirae Asset Capital, Revelation Partners, LYFE Capital, Gaingels, Section 32, LifeForce Capital, Timefolio Capital, BNY Investments Newton, Medical Excellence Capital
- Series A, Apr 1, 2020, $70M — ARCH Venture Partners, Domain Associates, Frazier Healthcare Partners, OrbiMed Advisors, Section 32
- Seed, Dec 12, 2019, $6.5M — ARCH Venture Partners, Domain Associates, OrbiMed Advisors, Alexandria Venture Investments, Axon Ventures, Section 32

## Investors

- ARCH Venture Partners (https://capitalatlas.ai/funds/arch-venture-partners) — Seed, Series A, Series B, Series C
- Domain Associates (https://capitalatlas.ai/funds/domain-associates) — Seed, Series A
- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Seed, Series A, Series B, Series C
- Alexandria Venture Investments (https://capitalatlas.ai/funds/alexandria-venture-investments) — Seed, Series B
- Axon Ventures — Seed, Series C
- Section 32 (https://capitalatlas.ai/funds/section-32) — Seed, Series A, Series B, Series C
- Frazier Healthcare Partners (https://capitalatlas.ai/funds/frazier-healthcare-partners) — Series A, Series B, Series C
- SG Growth Capital (https://capitalatlas.ai/funds/sg-growth-capital) — Series B
- GV (https://capitalatlas.ai/funds/gv) — Series B
- Mirae Asset Capital (https://capitalatlas.ai/funds/mirae-asset-capital) — Series B
- Revelation Partners (https://capitalatlas.ai/funds/revelation-partners) — Series B, Series C
- LYFE Capital — Series B, Series C
- Gaingels (https://capitalatlas.ai/funds/gaingels) — Series B
- LifeForce Capital (https://capitalatlas.ai/funds/lifeforce-capital) — Series B, Series C
- Timefolio Capital — Series B
- BNY Investments Newton — Series B
- Medical Excellence Capital (https://capitalatlas.ai/funds/medical-excellence-capital) — Series B, Series C
- Kite Pharma, Inc. — Series C
- Cormorant Asset Management (https://capitalatlas.ai/funds/cormorant-asset-management) — Series C
- BAM Elevate (https://capitalatlas.ai/funds/bam-elevate) — Series C
- Prebys Foundation — Series C